SAGE - Sage Therapeutics, Inc.

QQQ $ 446.25 $ -12.35 (-2.68 %)

DIA $ 404.28 $ -3.99 (-0.98 %)

SPY $ 539.90 $ -9.25 (-1.68 %)

TLT $ 99.49 $ -0.01 (-0.01 %)

GLD $ 230.65 $ -1.72 (-0.74 %)

Previous Close

$ 7.5

Open

Bid

$ 7.49 x 100

Ask

$ 7.52 x 400

Day's Range

-- - --

52 Week Range

$ 7.43 - $ 28.26

Volume

667,173

Average Volume

Market Cap

457.88M

Beta (5Y Monthly)

$ 1.35

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	07-31-2024	06-30-2024	10-Q
2	04-25-2024	03-31-2024	10-Q
3	02-14-2024	12-31-2023	10-K
4	11-07-2023	09-30-2023	10-Q
5	08-07-2023	06-30-2023	10-Q
6	05-02-2023	03-31-2023	10-Q
7	02-16-2023	12-31-2022	10-K
8	11-08-2022	09-30-2022	10-Q
9	08-02-2022	06-30-2022	10-Q
10	05-03-2022	03-31-2022	10-Q
11	02-24-2022	12-31-2021	10-K
12	11-02-2021	09-30-2021	10-Q
13	08-03-2021	06-30-2021	10-Q
14	05-04-2021	03-31-2021	10-Q
15	02-24-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-10-2020	06-30-2020	10-Q
18	05-07-2020	03-31-2020	10-Q
19	02-27-2020	12-31-2019	10-K
20	11-12-2019	09-30-2019	10-Q
21	08-06-2019	06-30-2019	10-Q
22	05-02-2019	03-31-2019	10-Q
23	02-19-2019	12-31-2018	10-K
24	11-06-2018	09-30-2018	10-Q
25	08-07-2018	06-30-2018	10-Q
26	05-03-2018	03-31-2018	10-Q
27	02-22-2018	12-31-2017	10-K
28	11-02-2017	09-30-2017	10-Q
29	08-03-2017	06-30-2017	10-Q
30	05-10-2017	03-31-2017	10-Q
31	02-24-2017	12-31-2016	10-K
32	11-03-2016	09-30-2016	10-Q
33	08-09-2016	06-30-2016	10-Q
34	05-06-2016	03-31-2016	10-Q
35	02-29-2016	12-31-2015	10-K
36	11-06-2015	09-30-2015	10-Q
37	08-12-2015	06-30-2015	10-Q
38	05-15-2015	03-31-2015	10-Q
39	03-06-2015	12-31-2014	10-K
40	11-13-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Truist Securities Maintains Hold on Sage T...
08/14/2024 14:14:38

Truist Securities analyst Joon Lee maintains Sage Therapeutics (NASDAQ:SAGE) with a Hold and lowers the price target from $1...

JP Morgan Maintains Neutral on Sage Therap...
08/06/2024 16:23:45

JP Morgan analyst Anupam Rama maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price target from $12 ...

HC Wainwright & Co. Reiterates Neutral on ...
08/02/2024 11:17:31

HC Wainwright & Co. analyst Douglas Tsao reiterates Sage Therapeutics (NASDAQ:SAGE) with a Neutral and maintains $25 pri...

Piper Sandler Maintains Overweight on Sage...
08/01/2024 16:08:49

Piper Sandler analyst Yasmeen Rahimi maintains Sage Therapeutics (NASDAQ: SAGE) with a Overweight and lowers the price targe...

Needham Reiterates Hold on Sage Therapeutics
08/01/2024 09:54:19

Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:SAGE) with a Hold.

Sage Anticipates That Its Existing Cash, C...
07/31/2024 20:23:16

FINANCIAL GUIDANCEBased upon the Company's current operating plan, Sage anticipates that its existing cash, cash equivalent...

Sage Therapeutics Q2 EPS $(1.70) Misses $(...
07/31/2024 20:14:50

Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(1.70) per share which missed the analyst consensus estimate of $...

Expert Outlook: Sage Therapeutics Through ...
07/30/2024 14:01:26

TD Cowen Downgrades Sage Therapeutics to H...
07/30/2024 09:55:16

TD Cowen analyst Ritu Baral downgrades Sage Therapeutics (NASDAQ:SAGE) from Buy to Hold and lowers the price target from $16...

Goldman Sachs Maintains Neutral on Sage Th...
07/26/2024 14:38:39

Goldman Sachs analyst Salveen Richter maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price target f...

Scotiabank Maintains Sector Outperform on ...
07/25/2024 17:58:58

Scotiabank analyst George Farmer maintains Sage Therapeutics (NASDAQ:SAGE) with a Sector Outperform and lowers the price tar...

JP Morgan Downgrades Sage Therapeutics to ...
07/25/2024 11:36:57

JP Morgan analyst Anupam Rama downgrades Sage Therapeutics (NASDAQ:SAGE) from Overweight to Neutral and lowers the price tar...

Baird Maintains Neutral on Sage Therapeuti...
07/25/2024 11:24:04

Baird analyst Joel Beatty maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price target from $15 to $13.

HC Wainwright & Co. Reiterates Neutral on ...
07/25/2024 10:41:05

HC Wainwright & Co. analyst Douglas Tsao reiterates Sage Therapeutics (NASDAQ:SAGE) with a Neutral and maintains $25 pri...

why-general-dynamics-shares-are-trading-lower-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Why General Dynamics Shares Are Trading Lo...
07/24/2024 17:26:11

sage-biogen-shelve-development-of-nervous-system-disorder-drug-after-data-disappoints

Sage, Biogen Shelve Development Of Nervous...
07/24/2024 15:05:05

Sage Therapeutics and Biogen will end further development of SAGE-324 in ET, focusing instead on evaluating future steps.

Needham Reiterates Hold on Sage Therapeutics
07/24/2024 12:15:22

Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:SAGE) with a Hold.

Sage, Biogen Report Results From Phase 2 K...
07/24/2024 10:33:58

netflix-to-rally-more-than-10-here-are-10-top-analyst-forecasts-for-friday

Netflix To Rally More Than 10%? Here Are 1...
07/19/2024 13:39:51

Mizuho Maintains Neutral on Sage Therapeut...
07/19/2024 12:09:45

Mizuho analyst Uy Ear maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price target from $18 to $16.